ArticleBritish journal of clinical pharmacology2007
A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation.
Article in British journal of clinical pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 52 citations in OpenAlex.
- Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center.Antimicrobial agents and chemotherapy · 2018Trial
- Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission.Antimicrobial agents and chemotherapy · 2009Trial
- Managing Infections in Burn Patients: Strategies and Considerations for Antimicrobial Dosing.European burn journal · 2025Review
- Application of Physiologically Based Pharmacokinetic Model to Delineate the Impact of Aging and Renal Impairment on Ceftazidime Clearance.Antibiotics (Basel, Switzerland) · 2024Article
- An Application of a Physiologically Based Pharmacokinetic Approach to Predict Ceftazidime Pharmacokinetics in a Pregnant Population.Pharmaceutics · 2024Article
- Population pharmacokinetics and dose optimization of ceftazidime in critically ill children.Frontiers in pharmacology · 2024Article
- Which Are the Best Regimens of Broad-Spectrum Beta-Lactam Antibiotics in Burn Patients? A Systematic Review of Evidence from Pharmacology Studies.Antibiotics (Basel, Switzerland) · 2023Review
- Predicting Volume of Distribution in Neonates: Performance of Physiologically Based Pharmacokinetic Modelling.Pharmaceutics · 2023Article
- Therapeutic Drug Monitoring of Antimicrobials in Critically Ill Obese Patients.Antibiotics (Basel, Switzerland) · 2023Article
- Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital-acquired/ventilator-associated bacterial pneumonia.Clinical and translational science · 2022Article
- After standard dosage of piperacillin plasma concentrations of drug are subtherapeutic in burn patients.Naunyn-Schmiedeberg's archives of pharmacology · 2019Observational
- Optimal aminoglycoside therapy following the sepsis: how much is too much?Iranian journal of pharmaceutical research : IJPR · 2013Article
- Review
- Increased creatinine clearance in polytrauma patients with normal serum creatinine: a retrospective observational study.Critical care (London, England) · 2011Article
- Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.British journal of clinical pharmacology · 2011Article
- Augmented renal clearance: implications for antibacterial dosing in the critically ill.Clinical pharmacokinetics · 2010Review
- Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.Clinical pharmacokinetics · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim of this study was to evaluate the disposition of ceftazidime in burn patients using a population pharmacokinetic approach, and to identify the clinical and biological parameters influencing its pharmacokinetics.
methodsThe development of the pharmacokinetic model was based on 237 serum ceftazidime concentrations from 50 burn patients. The determination of the pharmacokinetic parameters and the selection of covariates were performed using a nonlinear mixed-effect modelling method.
resultsA two-compartment model with first order elimination incorporating a proportional error model best fitted the data. Ceftazidime clearance (CL, l h(-1)) was significantly correlated with creatinine clearance (CL(CR)), and the distribution volume of the peripheral compartment (V2, l) was correlated with gender, mechanical ventilation and the CL(CR). The final model was defined by the following equations: Ceftazidime clearance was 6.1 and 5.7 l h(-1) for mechanically ventilated males and females, respectively, and 7.2 and 6.6 l h(-1) for nonventilated patients. The total volume of distribution was 31.6 and 49.4 l for mechanically ventilated males and females, respectively, and 22.8 and 28.1 l h (-1)for nonventilated patients.
conclusionsWe have shown that gender, mechanical ventilation and CL(CR) significantly influence the disposition of ceftazidime in burn patients. Interindividual variability in the pharmacokinetics of ceftazidime was significant and emphasizes the need for therapeutic monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.